# Dosing and administration

## The recommended dosing is co-administration of KRYSTEXXA with methotrexate[1-3]

**STEP 1**

4 weeks
**PRIOR TO TREATMENT**

**INITIATE**

15 mg methotrexate QW **WITH** 1 mg folic acid PO QD

- Confirm screening results for G6PD deficiency test
- Measure sUA level
- Stop oral ULTs 1 week prior to first infusion

**STEP 2**
**DURING TREATMENT WITH KRYSTEXXA**

8 mg intravenous infusion Q2W

**AND**

15 mg methotrexate QW **WITH** 1 mg folic acid PO QD

- Measure sUA levels within 48 hours prior to infusion
- Start premedications, including antihistamines and corticosteroids
- Gout flare prophylaxis is recommended for at least 6 months

KRYSTEXXA alone may be used in patients for whom methotrexate is not clinically appropriate.

- No calculation or dose adjustment required, including patients with chronic kidney disease[1]
- No loading dose recommended or required[1]

## ADMINISTERING KRYSTEXXA[1]

**Mix**

Using appropriate aseptic technique, withdraw 1 mL into a sterile syringe and inject into a 250 mL bag of normal or half-normal saline. Gently mix the bag by inverting several times and discard any unused portion of the remaining product. *Do not shake*

**Store**

If not administered immediately, it is recommended that the diluted solution be stored in the refrigerator and away from light

**Infuse**

Initiate infusion at a rate of 125 mL/h or slower via infusion pump or gravity feed. Infuse over no less than 2 hours. **DO NOT ADMINISTER AS INTRAVENOUS PUSH OR BOLUS**

**Monitor**

In the event of an infusion reaction, as clinically indicated, the infusion can be slowed or stopped and restarted at a slower rate. Observe patients for an appropriate period of time after administration


***Flip over to see reminders for storage and preparation of KRYSTEXXA.***

G6PD, glucose-6-phosphate dehydrogenase; PO, provided orally; QD, every day; QW, every week; Q2W, every 2 weeks; sUA, serum uric acid; ULT, urate-lowering therapy.

**Please see Important Safety Information on back cover of the infusion kit and enclosed Full Prescribing Information, including Boxed Warning.**

KRYSTEXXA® pegloticase

| REMINDERS FOR STORAGE AND PREPARATION[1] | |
|---|---|
| DO | ✓ Store inside the box and refrigerate between 2°C to 8°C (36°F to 46°F)<br>✓ Keep refrigerated until mixing<br>✓ Protect from light<br>✓ Visually inspect for particulate matter and ensure solution is clear and colorless<br>✓ Allow the diluted solution to come to room temperature and use within 4 hours |
| DO NOT | ✗ **Do not open the vial until the patient arrives and has been cleared for infusion**<br>✗ Do not shake the vial or diluted solution<br>✗ Do not freeze<br>✗ Do not use artificial heating to warm the vial<br>✗ Do not use if particulate matter is present<br>✗ Do not use if solution has any color |

**No special tubing or filtration is required for treatment with KRYSTEXXA**

***For step-by-step infusion instructions, see the Infusion Checklist included within this kit.***

**References: 1.** KRYSTEXXA (pegloticase) [prescribing information] Horizon. **2.** Botson J, et al. *J Clin Rheumatol*. 2022;28:e129-e134. **3.** Keenan RT, et al. *Rheumatol Ther*. 2019;6:299-304.

**Please see Important Safety Information on back cover of the infusion kit and enclosed Full Prescribing Information, including Boxed Warning.**

HORIZON.



KRYSTEXXA pegloticase